Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer

NCT01352884 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: AMP-224
DRUG: AMP-224

Sponsor

MedImmune LLC

Collaborators

[object Object]